SCHEMBL10242886

SCHEMBL10242886

CCCNC(=O)Cc1ccccc1-c1ccco1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
HPGD P15428 5/20 0.48
LMNA P02545 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TP53 P04637 1/20 0.48
GAA P10253 1/20 0.48
POLB P06746 4/20 0.43
PTPN7 P35236 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 3/20 0.39
MAPT P10636 2/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21767386 0.77 OPRM1 (0.43) ALDH1A1HPGDLMNARAB9ASMN1; SMN2
SCHEMBL10242926 0.77 ALDH1A1 (0.49) ALDH1A1HPGDLMNANPC1RAB9A
SCHEMBL5665316 0.76 AKR1B1 (0.48) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL10272753 0.75 MEN1 (0.53) ALDH1A1HPGDLMNANPC1RAB9A
SCHEMBL10242915 0.74 PRMT6 (0.53) ALDH1A1HPGDLMNANPC1RAB9A
SCHEMBL21401067 0.73 KMT2A (0.52) ALDH1A1HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL417395 0.71 PRMT6 (0.49) ALDH1A1HPGDLMNANPC1RAB9A
SCHEMBL10242917 0.71 ALDH1A1 (0.49) ALDH1A1HPGDLMNANPC1RAB9A
SCHEMBL6176277 0.71 HPGD (0.50) HPGDLMNASMN1; SMN2POLBMEN1
SCHEMBL12255250 0.71 NPSR1 (0.52) ALDH1A1HPGDNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 ALDH1A1 1939/4885HPGD 556/4885LMNA 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.